Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

From today many with stage 3B to stage 4 melanoma will now have wider access to Keytruda and the branded drug Tafinlar and Mekinist. Melanoma New Zealand Chief executive Andrea Newland says this ...

Oral melanoma is a rare cancer that forms in the mucosal tissues of the mouth. There may be no early symptoms, or a person may notice an area that is black or brown, with areas of gray, red ...

Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast This study identified ...

Melanoma is a type of skin cancer. Risk factors include overexposure to the sun, having fair skin, and a family history of melanoma, among others. Receiving an early diagnosis and getting prompt ...

Erasca also said that seeking partnerships for naporafenib, which is currently being studied in a Phase III trial with Novartis' MEK inhibitor Mekinist (trametinib) in patients with NRAS-mutant ...

which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.MEKINIST® is a registered trademark owned by or licensed to Novartis AG, its subsidiaries ...

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful ...

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful ...

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies ...